DCTH
Delcath Systems, Inc.
$17.14
+2.33%
2026-08-21
About Delcath Systems, Inc.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.
Key Fundamentals
P/E Ratio
1673.00
Forward P/E
371.78
EPS (TTM)
$0.01
ROE
0.5%
Revenue Growth (YoY)
20.6%
Profit Margin
0.6%
Debt/Equity
2.03
Price/Book
4.78
Beta
0.52
Market Cap
$580.5M
Avg Volume (10D)
1.0M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$17.42
60D Low
$10.20
Avg Volume
565K
Latest Close
$17.14
Get breakout alerts for DCTH
Sign up for Breakout Scanner to receive daily notifications when DCTH triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Delcath Systems, Inc. (DCTH) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors DCTH daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. DCTH operates in the Healthcare sector within the Medical Devices industry. Data is provided for informational purposes only and does not constitute financial advice.